Ripple Therapeutics receives funding support to advance R&D efforts in ophthalmic therapeutics

TORONTO, ON, CANADA / APRIL 27, 2022 - Ripple Therapeutics is pleased to announce that it is receiving advisory services and up to $500,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of Ripple’s lead product, IBE-814 IVT for the treatment of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO).  The project will entail analyzing the data generated from our ongoing clinical trial and the scale up of the product for the next stages on the path to commercialization.

“We are pleased to secure funding and advisory support from NRC IRAP," stated Wendy Naimark, Ripple Therapeutic’s Chief Technology Officer. "Work completed under this program will significantly enhance Ripple’s research and development efforts in ophthalmic therapeutics with controllable, sustainable drug delivery”.

Ripple is currently enrolling patients in RIPPLE-1, a Phase II clinical trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting DME and RVO patients.  The trial seeks to provide a much-needed treatment option: a safer steroid implant with an extended clinical benefit.

About Ripple Therapeutics

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery.  The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients.  Ripple has a full product pipeline in development.



Media Contact

Julie Fotheringham, V.P. Marketing, People & Culture

M: 416-951-7988 E: